OncLive News Network®

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss evolving treatment trends in acute lymphoblastic leukemia.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss evolving perioperative immunotherapy approaches in early-stage non–small cell lung cancer.

Experts at Ochsner MD Anderson Cancer Center review modern HAI therapy, share integration best practices, and discuss the role of the multidisciplinary care team.

Sponsored Content by Intera Oncology.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, explore emerging approaches to RAS inhibition in pancreatic ductal adenocarcinoma.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on updates in paroxysmal nocturnal hemoglobinuria.

Bijal Shah, MD, MS, and Jae Park, MD, deliver the key data and insights for CAR T-cell therapy in acute lymphoblastic leukemia.

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss updates in ADCs and more in ovarian cancer from ASCO 2025.

Guillermo Garcia-Manero, MD, details key updates in lower-risk myelodysplastic syndrome around the 2025 ASCO Annual Meeting.

On the Clock is a dynamic video series from Med News Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment trends and emerging data in ROS1-positive non–small cell lung cancer.

Lia Gore, MD, and Sarah K. Tasian, MD, discuss updates in the management of pediatric relapsed/refractory acute leukemia.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss novel treatment approaches in advanced melanoma after checkpoint inhibition.

Scott Kopetz, MD, PhD, FACP, and Mark A. Lewis, MD, discuss the evolving role of ctDNA in the management of colorectal cancer.

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, break down the latest data trends in platinum-resistant ovarian cancer.

Christian Marth, MD, PhD, and John Chan, MD, discuss the latest data trends in advanced endometrial cancer.

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss updates in the metastatic hormone-sensistive prostate cancer realm.

Floortje J Backes, MD, discusses evolving treatment considerations for platinum-resistant ovarian cancer.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss updates in acute lymphoblastic leukemia following ASH 2024.

Sangeetha Venugopal, MD, MS, discusses treatment trends and emerging data in the management of myelofibrosis.

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss key updates in the follicular lymphoma field following the 2024 ASH Annual Meeting

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, highlight treatment trends and key data emerging in the field of myelodysplastic syndromes.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss key data updates and trends in chronic myeloid leukemia after ASH 2024.

OncLive® will be premiering OncLive® News Network: On Location at the 2024 San Antonio Breast Cancer Symposium! Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

OncLive® will be premiering OncLive® News Network: On Location at the 2024 ASH Annual Meeting! Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss biomarker testing in non–small cell lung cancer.

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss updates in HCC and GI cancers from the 2024 ESMO Congress.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss updates in ALK-positive and ROS1-positive non–small cell lung cancer.

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss updates in acute myeloid leukemia following the 2024 SOHO Annual Meeting.

Yoshiaki Nakamura, MD, PhD, discusses how a methylation-based circulating tumor DNA assay can enhance minimal residual disease detection and improve prognosis in patients with previously treated stage II-III colorectal cancer.

Samuel Cytryn, MD, and David B. Zhen, MD, on updates in gastrointestinal cancers from the 2024 ASCO Annual Meeting and Gastrointestinal Cancers Symposium.